1. Home
  2. SCYX vs FCUV Comparison

SCYX vs FCUV Comparison

Compare SCYX & FCUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • FCUV
  • Stock Information
  • Founded
  • SCYX 1999
  • FCUV 2012
  • Country
  • SCYX United States
  • FCUV United States
  • Employees
  • SCYX N/A
  • FCUV N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • FCUV Industrial Machinery/Components
  • Sector
  • SCYX Health Care
  • FCUV Industrials
  • Exchange
  • SCYX Nasdaq
  • FCUV Nasdaq
  • Market Cap
  • SCYX 28.5M
  • FCUV 27.6M
  • IPO Year
  • SCYX 2014
  • FCUV N/A
  • Fundamental
  • Price
  • SCYX $0.70
  • FCUV $2.57
  • Analyst Decision
  • SCYX
  • FCUV
  • Analyst Count
  • SCYX 0
  • FCUV 0
  • Target Price
  • SCYX N/A
  • FCUV N/A
  • AVG Volume (30 Days)
  • SCYX 187.5K
  • FCUV 20.4K
  • Earning Date
  • SCYX 08-11-2025
  • FCUV 08-13-2025
  • Dividend Yield
  • SCYX N/A
  • FCUV N/A
  • EPS Growth
  • SCYX N/A
  • FCUV N/A
  • EPS
  • SCYX N/A
  • FCUV N/A
  • Revenue
  • SCYX $2,630,000.00
  • FCUV $408,887.00
  • Revenue This Year
  • SCYX $410.22
  • FCUV N/A
  • Revenue Next Year
  • SCYX $248.83
  • FCUV N/A
  • P/E Ratio
  • SCYX N/A
  • FCUV N/A
  • Revenue Growth
  • SCYX N/A
  • FCUV 6.49
  • 52 Week Low
  • SCYX $0.66
  • FCUV $1.50
  • 52 Week High
  • SCYX $2.21
  • FCUV $10.90
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 41.70
  • FCUV 27.18
  • Support Level
  • SCYX $0.67
  • FCUV $2.68
  • Resistance Level
  • SCYX $0.74
  • FCUV $2.99
  • Average True Range (ATR)
  • SCYX 0.04
  • FCUV 0.31
  • MACD
  • SCYX 0.00
  • FCUV -0.06
  • Stochastic Oscillator
  • SCYX 10.15
  • FCUV 9.25

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About FCUV Focus Universal Inc.

Focus Universal Inc offers smart devices, IoT products, and patented products and technologies for 5G telecommunications and network security. It is focused on commercializing its universal smart technology and financial reporting software. Its product line includes various digital, analog, and quantum light meters and filtration products, the Ubiquitor universal smart device, SEC Financial Reporting Software, and other smart devices and sensors. The company's reportable segments are Corporate and IoT, which derives maximum revenue, and Perfecular and Lusher. The Corporate and IoT segment includes its LED and IoT installation and management business (under Smart AVX), specializing in LED and display systems, home theaters, lighting control, automation, and integration.

Share on Social Networks: